• [ 49 ] It most often occurs in patients with an underlying thrombotic diathesis, including in those who are pregnant or who have a tumor, a chronic inflammatory disease, a clotting disorder, an infection, or a myeloproliferative disorder , such as polycythemia vera or paroxysmal nocturnal hemoglobinuria . (medscape.com)
  • His clinical interests include multiple myeloma, stem cell transplantation, and myeloproliferative neoplasm. (aamds.org)
  • Research interests are targeted therapy in CML and myeloproliferative neoplasms. (aamds.org)
  • Myelofibrosis (MF) is a hematopoietic stem cell malignancy classified as a myeloproliferative neoplasm (MPN). (cancernetwork.com)
  • The myeloproliferative neoplasms (MPNs) are a heterogeneous group of chronic hematological malignancies that are generally divided into the Philadelphia chromosome-positive (Ph-positive) MPNs, which refers to chronic myelogenous leukemia (CML) and the Philadelphia chromosome-negative (Ph-negative) MPNs. (cancernetwork.com)
  • The purpose of this research study is to test the safety and efficacy of cytokine induced memory-like (CIML) natural killer (NK) cells expanded with Interleukin-2 (IL-2) at preventing relapse in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or MDS and myeloproliferative neoplasm (MPN) overlap syndrome after a standard-of-care stem cell transplant. (survivornet.com)
  • This is a phase I/Ib study of the pre-emptive treatment using related donor-derived cytokine induced memory-like (CIML) natural killer (NK) cells combined with Interleukin-2 (IL-2) for participants with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and MDS/myeloproliferative neoplasm (MDS/MPN) overlap syndrome at high risk for post-allogeneic stem cell transplant (SCT) relapse. (survivornet.com)
  • this was the impetus for my current project examining CBL mutations in myelodysplastic and myeloproliferative neoplasms. (hematology.org)
  • His particular interest is in transplantation for multiple myeloma, lymphoma, myelodysplastic syndrome, acute leukemia and myeloproliferative neoplasms. (lvhn.org)
  • Myeloproliferative neoplasms (MPNs) are a group of disorders characterized by a proliferation of normally developed (nondysplastic) multipotent hematopoietic stem cells from the myeloid cell line . (amboss.com)
  • Less common MPNs, which are not associated with the driver mutations, include chronic eosinophilic leukemia (CEL), chronic neutrophilic leukemia , and myeloproliferative neoplasm , unclassifiable. (amboss.com)
  • Although myelofibrosis (MF) is the least common of the myeloproliferative neoplasms, it is the most lethal with a median survival of only 3-5 years. (bloodline.net)
  • Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, and anemia with nucleated and teardrop-shaped red blood cells. (msdmanuals.com)
  • Overview of Myeloproliferative Neoplasms Myeloproliferative neoplasms are clonal proliferations of bone marrow stem cells, which can manifest as an increased number of platelets, red blood cells (RBCs), or white blood cells (WBCs). (msdmanuals.com)
  • Analysis of gene mutations and clinic features in 108 patients with myeloproliferative neoplasm]. (cdc.gov)
  • Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. (cdc.gov)
  • Classification and Personalized Prognosis in Myeloproliferative Neoplasms. (cdc.gov)
  • Outcomes of Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) in Patients with CALR-Mutated Myelofibrosis compared to those patients with a JAK2-mutation. (ebmt.org)
  • He has published extensively on the immunobiology and application of hematopoietic cell transplantation, with nearly 200 scientific abstracts and peer-reviewed publications over the span of his career. (lvhn.org)
  • Patel S, Majhail N. Twitter Use in the Hematopoietic Cell Transplantation Community. (jmir.org)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Hematopoietic cell transplantation has become a cornerstone in the management of patients with lymphoma. (bloodline.net)
  • The effect of pre-transplant distress on immune reconstitution among adult autologous hematopoietic cell transplantation patients. (uw.edu)
  • Prospective neurocognitive function over 5 years after allogeneic hematopoietic cell transplantation for cancer survivors compared with matched controls at 5 years. (uw.edu)
  • To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
  • During a 6-month period, nine adult patients (median age: 47 years) who had hematological disorders and who were treated with HSCT (n = 7) or chemotherapy (n = 2) in a single hematology department developed hemorrhagic cystitis due to BKPyV infection. (elsevierpure.com)
  • In 2018, 8,250 patients received a liver transplant and 12,975 patients were on the waiting list for a liver transplant. (medscape.com)
  • [ 3 ] . An increasing number of orthotopic and living-donor liver transplantations are being performed to salvage patients with otherwise incurable end-stage liver disease (ESLD). (medscape.com)
  • [ 4 ] Doppler ultrasonography plays an important role in the postoperative management of liver transplantation. (medscape.com)
  • Spectral Doppler ultrasonographic waveform of the right hepatic artery in a 60-year-old man, 8 years after orthotopic liver transplantation. (medscape.com)
  • Lee et al retrospectively enrolled 75 patients who had undergone liver transpalantation and found that although MDCT in the late period should be interpreted with caution in patients with suspected biliary complication, MDCT is a reliable diagnostic technique for the identification of early and late abdominal complications after liver transplantation. (medscape.com)
  • Medicare conducted an analysis of the scientific evidence related to liver transplantation for patients with malignancies. (cms.gov)
  • However, our search of the literature did not produce a significant volume of literature, or literature of sufficiently sound methodology, to permit our staff to make a determination regarding liver transplantation for other malignant diagnoses, such as metastatic disease, bile duct carcinoma and epithelioid hemangioendothelioma. (cms.gov)
  • Attached is a request for a technology assessment that we need in order to develop a Medicare national coverage determination for liver transplantation for malignancies other than hepatocellular carcinoma. (cms.gov)
  • Currently, Medicare national coverage policy for liver transplantation excludes coverage for all malignancies. (cms.gov)
  • The body of literature related to liver transplantation for patients with HCC includes several comparison studies of sufficient sample size to clearly establish patient outcomes comparable to liver transplantation for non-malignant conditions. (cms.gov)
  • HCFA has determined that it does not possess sufficient internal expertise to fully and fairly review liver transplantation for these other malignancies, and that additional resources are required to facilitate this process. (cms.gov)
  • The purpose of the technology assessment is to provide information to assist HCFA in determining whether there is sufficient evidence to conclude whether liver transplantation for malignant diseases other than HCC meets the criteria of being reasonable and necessary under the Medicare law. (cms.gov)
  • We studied a patient with nonhepatic recurrence of hepatoma after successful liver transplantation. (jci.org)
  • Model parameters in liver and neoplasm were not significantly different, and glucose transport and phosphorylation were twofold and fourfold greater than in muscle. (jci.org)
  • The prognosis is poor in patients with Budd-Chiari syndrome who remain untreated, with death resulting from progressive liver failure in 3 months to 3 years from the time of the diagnosis. (medscape.com)
  • Scholars@Duke publication: Wilms Tumor After Orthotopic Liver Transplant in a Patient With Alagille Syndrome. (duke.edu)
  • We present a case of Wilms Tumor in a patient with Alagille syndrome 10 months after liver transplant. (duke.edu)
  • We also discuss the diagnostic and therapeutic challenges that can arise in a liver transplant patient with Alagille syndrome who subsequently develops a renal mass. (duke.edu)
  • Di Benedetto F, D'Amico G, Spaggiari M, Tirelli U, Berretta M. Onco-surgical management of colo-rectal liver metastases in older patients: a new frontier in the 3rd millennium. (uic.edu)
  • Indications and efficacy of conversion from tacrolimus- to sirolimus-based immunosuppression in pediatric patients who underwent liver transplantation for unresectable hepatoblastoma. (childrensmercy.org)
  • SRL-based immunosuppressive strategies in pediatric liver transplantation are not clearly defined, especially within the first year after liver transplant. (childrensmercy.org)
  • However, SRL may modulate TAC-associated kidney injury and may also have antiproliferative properties that are valuable in the management of patients following liver transplantation for HB. (childrensmercy.org)
  • A primary malignant neoplasm of epithelial liver cells. (lookformedical.com)
  • Liver cancer is the most common malignant neoplasm worldwide [ 1 ]. (aging-us.com)
  • Approximately 90% of patients with liver cancer have hepatocellular carcinoma (HCC) [ 2 ]. (aging-us.com)
  • Liver resection and transplantation are the main treatments for early-stage HCC. (aging-us.com)
  • Lymphoma is a malignant neoplasm that develops in the lymph nodes. (bvsalud.org)
  • Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive disease with historically poor outcomes. (medpagetoday.com)
  • For years the disease known as BPDCN had many different names, including natural killer cell leukemia/lymphoma, and only with the discovery that the disease is derived from plasmacytoid dendritic cells was the term established as blastic plasmacytoid dendritic cell neoplasm by the World Health Organization in 2008, and listed as its own entity in 2016. (medpagetoday.com)
  • This is a multicenter, open-label, Phase 1/2a dose escalation and expansion study of orally administered emavusertib (CA-4948) monotherapy in adult patients with Acute Myelogenous Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). (rochester.edu)
  • Here are the session recordings and the presentations for the 2023 Omaha Patient and Family Hybrid Conference. (aamds.org)
  • Immunohistochemistry and quantitative polymerase chain reaction were used to analyze tumor samples from 172 HCC patients. (nih.gov)
  • TLR3 expression in patient samples correlated with NK-cell activation, NK- and T-cell tumor infiltration, and inversely correlated with tumor parenchyma cell viability. (nih.gov)
  • Tumor glucose use in patients with non-islet-cell tumors has been difficult to measure, particularly in hepatoma, because of hepatic involvement by neoplasm. (jci.org)
  • While the biospecimens used in this study are from lung cancer patients, if successful, this assay will have broad applicability to all tumor types for which antigen-specific TCRs can be studied. (swimacrossamerica.org)
  • Most had monomorphic histology, 85% were associated with Epstein-Barr virus, 25% of patients had tumor involvement of the renal graft, and 12.5% ​​had primary central nervous system lymphoma. (univalle.edu.co)
  • Nonfunctioning neuroendocrine neoplasms can still cause symptoms relating to tumor size and location such as obstruction or internal bleeding. (rarediseases.org)
  • It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. (lookformedical.com)
  • Some factors such as individual treatment strategy, according to the histology of the primary tumor, plan of treatment strategies carried out in a multidisciplinary manner, risk-benefit of radiotherapy, assessment of the degree of spinal instability, improvement in communication and referral between specialists in oncology showed an increase in the survival of these patients. (bvsalud.org)
  • The aim of this population-based study was to describe the magnitude and panorama of late effects among patients treated with or without high-dose chemotherapy with autologous stem cell transplantation (HD-ASCT). (lu.se)
  • Outcomes of allogeneic or autologous stem cell transplantation followed by maintenance chemotherapy in adult patient with B-ALL in CR1 with no detectable minimal residual disease. (stembook.org)
  • The role of high-dose chemotherapy (HDCT) in patients with refractory breast cancer is not well established. (elsevierpure.com)
  • Forty-two female patients (median age of 46 years) with breast cancer refractory to neoadjuvant chemotherapy received HDCT (cyclophosphamide, carmustine and thiotepa) supported by an autologous peripheral blood stem cells transplant. (elsevierpure.com)
  • Their disease had been refractory (defined as less than partial response) to one (18 patients) or two (24 patients) regimens of neoadjuvant chemotherapy. (elsevierpure.com)
  • Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. (elsevierpure.com)
  • All patients received at least one cycle of CDDP-based chemotherapy prior to transplant. (childrensmercy.org)
  • None of these patients had had previous chemotherapy for metastatic disease. (psu.edu)
  • For patients with metastatic breast cancer and no previous chemotherapy for metastatic disease, we have no evidence for a difference between CY and CY-Etoposide as the mobilization regimen. (psu.edu)
  • Patients with PTCL receiving chemotherapy with curative intent were registered and prospectively monitored. (e-crt.org)
  • Rapidly progressive, chemotherapy-incurable acute leukemia Overview of Leukemia develops in about 30% of patients. (msdmanuals.com)
  • See the images below of transplantation complications. (medscape.com)
  • Within this observation period, no difference in the rate of these complications, including secondary neoplasms, was observed between patients treated with and without HD-ASCT. (lu.se)
  • In patients with known disease, it provides important information for staging, evaluation of response to therapy, identification of recurrence or complications of therapy. (eurorad.org)
  • Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. (lookformedical.com)
  • The spine is the most frequent area of bone metastasis in patients with systemic neoplastic disease. (bvsalud.org)
  • He is also heavily involved in researching novel cellular therapies that could lead to better outcomes and quality of life for patients in the near future, and his work in this area will be a major asset to our program. (lvhn.org)
  • Similarly, the outcomes of myeloablative conditioning and reduced-intensity conditioning regimens for allo-HCT and their relationship with pretransplant consolidation cycles for patients in first complete remission are also unknown. (ascopost.com)
  • This large retrospective analysis on behalf of the CIBMTR shows again that among patients eligible for allo-HCT, only one induction cycle to achieve first complete remis sion, particularly when combined with one consolidation therapy, is associated with better outcomes after myeloablative conditioning and not reduced-intensity conditioning. (ascopost.com)
  • Compared with the poor outcomes of patients who received allo-HCT during refractory (active) disease, the outcomes of patients who received more than one induction cycle to achieve complete remission is somewhat better but remains unsatisfactory. (ascopost.com)
  • Much of the current confusion and controversy in MDS treatment stems from the lack of consensus on which therapies to use in which patients, and what realistic outcomes might be. (bloodline.net)
  • Galectin-1 expression was positively correlated with poor prognostic outcomes for HCC patients. (aging-us.com)
  • We conducted a nationwide, multicenter, prospective registry study for newly diagnosed patients with peripheral T-cell lymphoma (PTCL) to better define the clinical characteristics, treatment patterns, survival outcomes, and the role of upfront autologous stem cell transplantation (ASCT) in these patients. (e-crt.org)
  • I have expertise in novel therapies for acute myeloid leukemia, stem cell mobilization and homing, as well as stem cell transplantation. (rochester.edu)
  • Of these patients 45% went on to undergo stem-cell transplantation, and survival rates at 18 and 24 months were 59% and 52%, respectively. (medpagetoday.com)
  • Of 23 patients in the study, 52% had at least two prior therapies, 52% had received prior intensive therapies, 22% had prior allogeneic stem cell transplant, and 43% had prior exposure to tagraxofusp. (medpagetoday.com)
  • Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field. (cancernetwork.com)
  • Hematopoietic stem cell transplantation is the only potentially curative therapy, but it is only an option for select patients. (cancernetwork.com)
  • The Composite Immune Risk Score predicts overall survival after allogeneic hematopoietic stem cell transplantation: A retrospective analysis of 1838 cases. (stembook.org)
  • Hematopoietic stem cell transplantation from an infected SARS-CoV2 haploidentical donor: A case report. (stembook.org)
  • The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. (stembook.org)
  • Refractory patients with favorable/intermediate-risk acute myeloid leukemia benefit from azacytidine maintenance therapy following allogeneic hematopoietic stem cell transplantation. (stembook.org)
  • If there is no clinical evidence of a change in cardiovascular function from the time of pre-transplantation ECHO (per FACT standards should be performed within 6 weeks of stem cell infusion), then there is no need to repeat it. (survivornet.com)
  • Adult patients (age ≥ 18) eligible for and planned to undergo a standard-of-care reduced intensity conditioning (RIC) HLA-matched related or related haploidentical allogeneic stem cell transplant using PTCY-based GVHD prophylaxis. (survivornet.com)
  • As a transfusion medicine physician, numerous cases I see involve patients with transfusion-dependent myeloid diseases or graft-versus-host disease after allogeneic stem cell transplantation for a myeloid disease. (hematology.org)
  • It is an honor to bring stem cell transplantation and cellular therapies to adults in the Lehigh Valley and its surrounding communities," Dr. Toor says. (lvhn.org)
  • Allogeneic hematopoietic stem cell transplantation is the only curative treatment. (amboss.com)
  • Hematopoietic stem cell transplantation can be considered in young patients with chronic myelogenous leukemia in chronic phase if a human leukocyte antigen (HLA)-matched donor is available. (medscape.com)
  • This phase II trial studies the side effect of busulfan, fludarabine phosphate, and post-transplant cyclophosphamide in treating patients with blood cancer undergoing donor stem cell transplant. (mdanderson.org)
  • Patients with hematological malignancies (HMs) are at a continuous risk for immunodeficiency, related either to the own malignancy or to the associated therapies, such as antineoplastic drug administration or hematopoietic stem-cell transplantation (HSCT). (lww.com)
  • Autologous hematopoietic stem cell transplantation (aHSCT) is a well-established treatment for hematologic malignancies such as multiple myeloma (MM) and non-Hodgkin lymphoma (NHL). (bloodline.net)
  • BK polyomavirus (BKPyV) is recognized as a pathogen that causes diseases such as hemorrhagic cystitis and nephritis after allogeneic hematopoietic stem cell transplantation (HSCT) or renal transplantation. (elsevierpure.com)
  • some patients will need ongoing maintenance therapy depending on how much consolidation treatment they have received, as well as if they had a stem cell transplant. (oncolink.org)
  • Here we present an analysis of SPM incidence and profile the SPM type to determine the impact of autologous stem cell transplantation (ASCT) and lenalidomide exposure in 4358 patients treated on study. (nyu.edu)
  • Aim: Present a case report of dental care provided to a non-Hodgkin lymphoma patient with an urgent need for hematopoietic stem cell transplant. (bvsalud.org)
  • Treatment is often supportive, but Janus kinase 2 (JAK2) inhibitors, such as ruxolitinib , fedratinib , or pacritnib, may decrease symptoms and stem cell transplantation may be curative. (msdmanuals.com)
  • Australasian Trends in Allogeneic Stem Cell Transplantation for Myelofibrosis in the Molecular Era: A retrospective analysis from The Australasian Bone Marrow Transplant Recipient Registry. (cdc.gov)
  • Application of prophylactic or pre-emptive therapy after allogeneic transplantation for high-risk patients with t(8;21) acute myeloid leukemia. (stembook.org)
  • Patients are kept under close observation because of the risk of developing acute myeloid leukemia ( AML ). (amboss.com)
  • Dr. Sallman's research focuses on the development of novel, targeted therapeutic strategies for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). (moffitt.org)
  • Phase I and II clinical trials) for patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) based on the underlying mutational drivers of each disease. (moffitt.org)
  • As an example, Dr. Sallman has focused research and clinical trial efforts on patients who have TP53 mutation (often associated with complex genes/cytogenetics) given their high risk of transformation to acute leukemia and poor survival. (moffitt.org)
  • Acute myeloid leukemia (AML) and related neoplasms. (oncolink.org)
  • A New Complex Karyotype Involving a KMT2A-r Variant Three-Way Translocation in a Rare Clinical Presentation of a Pediatric Patient with Acute Myeloid Leukemia. (cancerindex.org)
  • Patients with childhood acute myeloid leukemia (AML) with complex karyotypes (CKs) have a dismal outcome. (cancerindex.org)
  • Studies on late effects in patients with mantle cell lymphoma (MCL) are becoming increasingly important as survival is improving, and novel targeted drugs are being introduced. (lu.se)
  • Most of the patients died from their lymphoma and not from another cause or treatment complication. (lu.se)
  • The use of autologous transplant in Hodgkin's and non-Hodgkin's lymphoma has significantly improved the survivals of patients with relapsed disease. (bloodline.net)
  • To describe the clinical response, overall and graft survival of patients in our center with this complication after kidney transplantation, which received rituximab as part of their treatment as well as conversion to m-TOR. (univalle.edu.co)
  • Titrate the dosage in each individual patient based on biochemical and/or clinical response. (guidelinecentral.com)
  • He has published significantly on this topic including recently in highly regarded journals including Leukemia and Haematologica and these work form the foundation of the clinical trials that he is bringing to patients in order to improve their quality of life and survival. (moffitt.org)
  • CONCLUSIONS: Homozygosity at one or more HLA-I loci may serve as biomarker to predict patients who are unlikely to experience severe irAEs among patients with NSCLC and treated with anti-PD1/PDL1, but less likely to derive clinical benefit. (bvsalud.org)
  • In this article, we provide updated data on ruxolitinib therapy for patients with myelofibrosis and offer expert opinion on the appropriate use of this agent in the community practice. (cancernetwork.com)
  • The peripheral smear below shows leukoerythroblastosis and giant platelets in a patient with myelofibrosis. (medscape.com)
  • Peripheral smear of a patient with agnogenic myeloid metaplasia (myelofibrosis) shows leukoerythroblastosis. (medscape.com)
  • Phase II study of ruxolitinib given pre-, peri- and post-allo-HCT for patients with primary or secondary myelofibrosis (ClinicalTrials.gov identifier NCT03427866). (ascopost.com)
  • In many patients, myelofibrosis is asymptomatic. (msdmanuals.com)
  • Molecular profile of patients with myelofibrosis: a 10-year experience. (cdc.gov)
  • Genomic characterization and prognostication applied to a Brazilian cohort of patients with myelofibrosis. (cdc.gov)
  • Screening for ASXL1 and SRSF2 mutations is imperative for treatment decision-making in otherwise low or intermediate-1 risk patients with myelofibrosis. (cdc.gov)
  • While not a curative option, ruxolitinib offers great palliative potential and results in significant reduction in splenomegaly and improvement in constitutional symptoms in the majority of treated patients, thus improving their quality of life and performance status. (cancernetwork.com)
  • TLR3 expression was also associated with longer survival in HCC patients (hazard ratio of survival = 2.1, 95% confidence interval = 1.3 to 3.4, P = .002). (nih.gov)
  • Of the previously treated patients, the response rate was 67%, and the median overall survival was 8.5 months. (medpagetoday.com)
  • Additionally, ruxolitinib is the only agent that has demonstrated a survival benefit in patients with MF. (cancernetwork.com)
  • For many years palliation of symptoms with alkylating agents or hydroxyurea was the only therapy available and this had little or no effect on the survival of patients with MF. (bloodline.net)
  • Historically, patients suffering the cited eosinophil-related syndromes were evaluated for causes of their eosinophilia such as those due to allergic disease, parasite or fungal infection, autoimmune disorders, and various well-known hematological malignancies (e.g. (wikipedia.org)
  • These state-of-the-art treatments are lifesaving for many patients with hematologic malignancies. (lvhn.org)
  • Pancreatic neuroendocrine neoplasms (pNENs) are an increasingly common group of malignancies that arise within the endocrine tissue of the pancreas. (rarediseases.org)
  • 01). Treatment-related mortality was similar for patients with primary induction failure vs those in first complete remission after myeloablative or reduced-intensity conditioning allo-HCT (Table 1). (ascopost.com)
  • Thirty patients had complete remission, eight had a PR, one had a minor response, and three had progressive disease. (elsevierpure.com)
  • In a hospital-based, retrospective, case-control study in 20112012, adult cases of lymphoproliferative disorders (n = 130) were recruited from outpatient clinics in Menoufia, Egypt, while controls (n = 130) were age- and sex-matched fracture patients. (who.int)
  • The study was carried out to exhaust the scientific literature regarding surgery associated with radiotherapy in patients suffering from metastatic spinal cord compression and to assist in the decision of oncology physicians and professionals in choosing the best treatment for the patient. (bvsalud.org)
  • The researchers carried out a descriptive study using bibliometric and scientometric methods and found that the combination of surgery with postoperative radiotherapy is effective and more efficient than these alone for the treatment of patients affected by metastatic neurological compression. (bvsalud.org)
  • ORFADIN ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. (rxlist.com)
  • For patients who have difficulties swallowing intact tablets, including pediatric patients, the tablets can be disintegrated in water and administered using an oral syringe. (guidelinecentral.com)
  • The relationship between the oral and gut microbiome of pediatric patients with hematologic disorders and Graft-versus-Host Disease (GVHD) after transplantation. (who.int)
  • Are next-generation sequencing results knocking on Heaven's door for transplantation planning in chronic myelomonocytic leukemia? (haematologica.org)
  • A classic example of such a disease is chronic myelogenous leukemia, a neoplasm commonly caused by a mutation that creates the BCR-ABL1 fusion gene (see Philadelphia chromosome). (wikipedia.org)
  • Absent these causes, patients were diagnosed in the World Health Organization's classification as having either 1) Chronic eosinophilic leukemia, not otherwise specified, (CEL-NOS) if blood or bone marrow blast cells exceeded 2% or 5% of total nucleated cells, respectively, and other criteria were met or 2) idiopathic hypereosinophilic syndrome (HES) if there was evidence of eosinophil-induced tissue damage but no criteria indicating chronic eosinophilic leukemia. (wikipedia.org)
  • The current study attempts to demonstrate the existence of double minute chromosomes via FLT3 gene amplification in a patient diagnosed with chronic myelomonocytic leukemia (CMML). (hindawi.com)
  • Here, to our best knowledge, we present the first case of amplification encompassing the FLT3 gene acting as dmin in a patient with chronic myelomonocytic leukemia (CMML). (hindawi.com)
  • Dasatinib (Sprycel): Indicated for the treatment of adult patients with chronic myeloid leukemia in chronic, accelerated, or myeloid or lymphoid blast phase who are resistant or intolerant to prior therapy including imatinib. (medscape.com)
  • With a combination of these tools, many patients can be spared the morbidity and potential mortality associated with repeat operation or retransplantation. (medscape.com)
  • INTRODUCTION: Biomarkers that predict the risk of immune-mediated adverse events (irAEs) among patients with non-small cell lung cancer (NSCLC) may reduce morbidity and mortality associated with these treatments. (bvsalud.org)
  • Mortality due to progressive myeloma was reduced in patients receiving lenalidomide maintenance, noted to be 16.6% compared 22.6% in those observed in TE patients and 32.7% compared to 41.5% in TNE patients. (nyu.edu)
  • SPM related mortality was low, 1.8% and 6.1% in TE and TNE lenalidomide maintenance patients, respectively, compared to 0.4% and 2.8% in those being observed. (nyu.edu)
  • Our patients depend on blood and platelet donations. (mdanderson.org)
  • Engraftment was rapid, with patients reaching a neutrophil count of 0.5 x 10 9 /L a median of 9 days (range 7-23) and a platelet count of 20 x 10 9 /L a median of 12 days (range 8-28) after transplantation. (psu.edu)
  • The discovery of an activating point mutation in the Janus kinase 2 gene ( JAK2 V617F) in a significant portion of patients with MPNs led to improved understanding of the pathobiology of these disorders and prompted rapid development of JAK inhibitors. (cancernetwork.com)
  • The approval was based on findings from a single-institution phase 2 trial (NCT02649972) conducted by Memorial Sloan Kettering Cancer Center (MSKCC) and Genentech in a population of adult patients with histiocytic disorders. (cancernetwork.com)
  • While many of the Cancer Institute's patients are able to receive the most advanced therapies for their diagnosis close to home, people who needed hematopoietic cell transplant or cellular immunotherapy have always needed to travel outside of the Lehigh Valley for these treatments. (lvhn.org)
  • Methods: Myeloma XI is a large, phase III randomised trial in-which lenalidomide was used at induction and maintenance, in transplant eligible (TE) and non-eligible (TNE) newly diagnosed patients (NCT01554852). (nyu.edu)
  • Pemmaraju presented a study at the recent American Society of Hematology's virtual meeting evaluating the safety and efficacy of IMGN632 in patients with relapsed/refractory BPDCN. (medpagetoday.com)
  • Oral MEK1/2 inhibitor cobimetinib (Cotellic) has received approval by the FDA for the treatment of patients with histiocytic neoplasms including Erdheim-Chester disease, Rosai-Dorfman disease, and Langerhans cell histiocytosis. (cancernetwork.com)
  • Nelson J. Chao, MD, MBA, and his colleagues discussed the use of ruxolitinib as treatment for patients with graft-vs-host disease. (cancernetwork.com)
  • Historically, patients with this debilitating disease have had limited treatment options, and disease-modifying agents were not available. (cancernetwork.com)
  • In this retrospective analysis, the investigators assessed the impact of the number of induction and consolidation cycles and disease status on the success of allo-HCT in 3,113 patients with AML from 2008 to 2019. (ascopost.com)
  • In seven of 13 patients whose disease was inoperable before HDCT, it became operable. (elsevierpure.com)
  • After a median follow-up of 42 months, 21 patients were alive, and 15 remained disease free. (elsevierpure.com)
  • Computed tomography is easy to perform and allows a provisional diagnosis in patients without known disease. (eurorad.org)
  • The modality of treatment depends on the stage of the disease, but many patients are treated with chemoradiation therapy alone. (eurorad.org)
  • Being able to receive these therapies close to home is an absolute advantage for these patients. (lvhn.org)
  • However, for patients with a KMT2A rearrangement (KMT2A-r), the prognosis appears to depend on the fusion partner gene rather than the karyotype structure. (cancerindex.org)